Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study

Abstract

ClinicalTrials.gov identifier: NCT03381950.

Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD‐REIN cohort

“…A total of 3033 patients were included. Details of the study protocol have been published elsewhere . The study protocol was approved by the institutional review board at the French National Institute of Health and medical research (INSERM; reference: IRB00003888).…”

“…Patient‐level forms were completed by trained clinical research associates (CRAs) on the basis of a patient interview and the inspection of medical records. Detailed definitions of comorbidities have been published elsewhere . Self‐administered patient questionnaires were used to assess medication adherence on the Girerd score and frequency of consultation to family physicians and specialist physicians.…”

Reply to “Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!” by Stamp et al.

“…In the CKD‐REIN cohort of 3033 patients, 3011 had at least one drug prescription in the 3 months immediately prior to inclusion. The objective of our study was to assess the prevalence and determinants of inappropriate drug prescription (ie, contraindicated drugs and inappropriately high doses of indicated drugs) with regard to kidney function in patients with CKD receiving nephrology care.…”

Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA

“…The prevalence of CKD is considerable and still rising; ultrasound is the only imaging modality used in the majority of patients and provides only limited information. In large CKD cohorts, only ∼25% of all CKD patients under the care of nephrologists have undergone a biopsy, and in a similar proportion the cause of CKD is designated as unknown [ 6 , 7 ]. New imaging methods to identify, characterize and track kidney damage at an early stage are urgently needed; such methods will also have the potential to contribute to the development and successful application of new therapies.…”